Singlomics
Latest round
- Series B
Last raised
- Feb 2022
Total raised
- $62M
Investors
- 12
About Singlomics
Established in 2020 and based in Beijing, China, the company has a team of 26 people, of which the core scientific team members have graduated from Harvard University, Peking University, Fudan University and other well-known institutions. The co-founder of the company professor Xiaoliang Xie is an internationally renowned biophysical chemist and a member of the US National Academy of Sciences, the CEO Dr. Qian Shi used to work in Apollomics and other companies in the field of oncology. The company owns a single cell sequencing platform, is a novel drug development strategy which can be used to develop antibody-based drugs. Based on the above platform, the company's drug development pipeline consists of three main directions: covid-19 neutralizing antibody, the main products are DXP-593 and DXP-604, which can be used to defend Delta and Omicron; antibodies to infectious diseases for resistance to chronic hepatitis B; and drugs applied in oncology treatment.
Who invested in Singlomics
12 investors across 2 rounds
See all investors in Singlomics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Singlomics
Who invested in Singlomics?
Singlomics has 12 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Singlomics raised?
Singlomics has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Singlomics last raise money?
Singlomics's most recent round on record is a Series B, in Feb 2022.
What does Singlomics do?
Established in 2020 and based in Beijing, China, the company has a team of 26 people, of which the core scientific team members have graduated from Harvard University, Peking University, Fudan University and other well-known institutions.
Where is Singlomics headquartered?
Singlomics is headquartered in Beijing, China.
Which VCs invest in companies like Singlomics?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back pharmaceuticals companies at Singlomics's stage. Their profiles are linked below.
VCs backing pharmaceuticals startups at Series B
Raising like Singlomics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.